Stay updated with breaking news from Philippe Calais. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BOSTON, Jan. 12, 2024 -- TransCode Therapeutics, Inc. , the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported further steps in its...
An Open Letter to Shareholders of TransCode Therapeutics, Inc....
/PRNewswire/ -- MatriSys BioScience, a private, clinical-stage pharmaceutical company focused on developing live biotherapeutic products (LBPs) for chronic...
Share: Industry Experts Provide Added Depth to Board of Directors and Advisory Board TransCode Therapeutics today announced that it has recently elected a Chairman of its Board of Directors, appointed two new Independent Directors to the Board, and appointed a new member to its Advisory Board. Philippe Calais, Pharm D, Ph.D., President, Chief Executive Officer and a director of MatriSys Bioscience, Inc., has been elected Chairman of the Board of Directors of TransCode. Dr. Calais has served on TransCode's Board of Directors since October 2018. With an extensive background in drug development,...